Form 4: Black Diamond Therapeutics Executive Erika Jones Reports Stock and Option Awards

Erika Jones, a Senior Vice President at Black Diamond Therapeutics, reported the acquisition of restricted stock units and stock options.

Summary

• On January 30, 2025, Erika Jones, Senior Vice President, Finance and Corporate Controller at Black Diamond Therapeutics, reported transactions involving the company's securities.
• Jones was granted 75,000 Restricted Stock Units (RSUs) and an option to purchase 125,000 shares of common stock at an exercise price of $2.52.
• Following these transactions, Jones beneficially owns 85,150 shares of common stock and options to purchase 125,000 shares.
• The RSUs vest in two tranches: 50% on January 30, 2026, and the remaining 50% on January 30, 2027, contingent upon continued service.
• The stock options vest 25% on January 30, 2026, with the remainder vesting in 36 equal monthly installments thereafter, also contingent upon continued service.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock and option grants, which is neither inherently positive nor negative. The sentiment is neutral.

Positives

• The grant of RSUs and stock options to a key executive like Erika Jones can be seen as an incentive to align her interests with the long-term success of Black Diamond Therapeutics.
• The vesting schedules for both the RSUs and stock options encourage continued service and commitment from the executive.

Industry Context

Form 4 filings are a routine part of the US financial market, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The grant of equity to executives can align their interests with those of shareholders, potentially leading to increased long-term value.

Key Dates